Abstract |
Ex-vivo gene editing in T lymphocytes paves the way for novel concepts of immunotherapy. One of those strategies is directed at the protection of CD4+-T helper cells from HIV infection in HIV-positive individuals. To this end, we have developed and optimised a CCR5-targeting TALE nuclease, CCR5-Uco-hetTALEN, mediating high-efficiency knockout of C-C motif chemokine receptor 5 (CCR5), the HIV co-receptor essential during initial infection. Clinical translation of the knockout approach requires up-scaling of the manufacturing process to clinically relevant cell numbers in accordance with good manufacturing practice (GMP). Here we present a GMP-compatible mRNA electroporation protocol for the automated production of CCR5-edited CD4+-T cells in the closed CliniMACS Prodigy system. The automated process reliably produced high amounts of CCR5-edited CD4+-T cells (>1.5 × 109 cells with >60% CCR5 editing) within 12 days. Of note, about 40% of total large-scale produced cells showed a biallelic CCR5 editing, and between 25 and 42% of produced cells had a central memory T-cell phenotype. In conclusion, transfection of primary T cells with CCR5-Uco-hetTALEN mRNA is readily scalable for GMP-compatible production and hence suitable for application in HIV gene therapy.
|
Authors | Lea Isabell Schwarze, Tanja Sonntag, Stefan Wild, Sabrina Schmitz, Almut Uhde, Boris Fehse |
Journal | Gene therapy
(Gene Ther)
Vol. 28
Issue 9
Pg. 572-587
(09 2021)
ISSN: 1476-5462 [Electronic] England |
PMID | 33867524
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2021. The Author(s). |
Chemical References |
- CCR5 protein, human
- Receptors, CCR5
|
Topics |
- CD4-Positive T-Lymphocytes
- Gene Editing
- HIV Infections
(therapy)
- Humans
- Receptors, CCR5
(genetics)
- T-Lymphocytes
|